Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INITIATED ENROLLMENT OF PHASE 1 STUDY OF PRT12396, MUTANT-SELECTIVE JAK2V617F INHIBITOR IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND MYELOFIBROSIS (MF)

PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILMINGTON, DEL., APRIL 20, 2026 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD) (PRELUDE OR THE COMPANY), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN OFFERING OF 18,018,014 SHARES OF ITS VOTING COMMON STOCK (THE COMMON STOCK) AT A PRICE OF $4.44 PER SHARE, AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOSE, PRE-FUNDED WARRANTS TO PURCHASE UP TO 2,252,252 SHARES OF ITS COMMON STOCK AT A PRICE OF $4.4399 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES, THE TOTAL GROSS PROCEEDS TO PRELUDE ARE APPROXIMATELY $90.0 MILLION. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT APRIL 21, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

PRELUDE THERAPEUTICS ANNOUNCES PRICING OF $90.0 MILLION UNDERWRITTEN OFFERING

DATA DEMONSTRATE POTENTIAL FOR DIFFERENTIATED EFFICACY AND SAFETY PROFILE, INCLUDING COMPLETE RESPONSES AS MONOTHERAPY IN MULTIPLE CDX AND PDX MODELS OF HR+/HER2- BREAST CANCER

PRELUDE THERAPEUTICS PRESENTS PRECLINICAL DATA FROM DEVELOPMENT CANDIDATE, PRT13722, A FIRST-IN-CLASS, ORALLY BIOAVAILABLE, POTENT AND HIGHLY SELECTIVE KAT6A DEGRADER AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026

WILMINGTON, DEL., APRIL 15, 2026 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD) (PRELUDE THERAPEUTICS OR THE COMPANY), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THAT DR. CHARLES MORRIS WILL JOIN THE COMPANY AS CHIEF MEDICAL OFFICER EFFECTIVE, APRIL 20, 2026.

PRELUDE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF CHARLES MORRIS, M.D. AS CHIEF MEDICAL OFFICER

WILMINGTON, DEL., MARCH 17, 2026 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THAT A POSTER WITH PRECLINICAL DATA ON THE COMPANY'S ORAL KAT6A SELECTIVE DEGRADER (PRT13722) HAS BEEN ACCEPTED FOR PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026, TAKING PLACE FROM APRIL 17-22.

PRELUDE THERAPEUTICS ANNOUNCES ACCEPTANCE OF PRECLINICAL ABSTRACT FOR PRT13722, A FIRST-IN-CLASS ORAL KAT6A SELECTIVE DEGRADER AT THE 2026 AACR ANNUAL MEETING

RECEIVED FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR PRT12396, MUTANT-SELECTIVE JAK2V617F INHIBITOR IN THE FIRST QUARTER OF 2026 PHASE 1 STUDY OF PRT12396 IN PATIENTS WITH POLYCYTHEMIA VERA AND MYELOFIBROSIS ANTICIPATED TO INITIATE BY Q2 2026 PRECLINICAL DEVELOPMENT AND IND ENABLING STUDIES FOR PRT13722, HIGHLY-SELECTIVE ORAL KAT6A DEGRADER UNDERWAY, AND THE COMPANY INTENDS TO FILE THE IND FOR PRT13722 IN MID-2026 WITH PHASE 1 STUDY INITIATION ANTICIPATED IN THE 2 ND HALF OF 2026 CURRENT CASH RUNWAY EXPECTED INTO SECOND QUARTER OF 2027 WITH $106 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2025 WILMINGTON, DEL., MARCH 10, 2026 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED AN UPDATE ON ITS R&D PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

PRELUDE THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES PROGRAM OUTLOOK FOR 2026

FIRST DISCLOSURE OF PRT12396, A JAK2V617F-SELECTIVE JH2 INHIBITOR DEMONSTRATES DISEASE MODIFYING POTENTIAL IN MYELOPROLIFERATIVE NEOPLASMS

PRELUDE THERAPEUTICS PRESENTS DATA AT THE 2025 ASH ANNUAL MEETING FROM ITS MYELOPROLIFERATIVE NEOPLASM (MPN) PROGRAMS

NEW YORK , NOV. 20, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF PRELUDE THERAPEUTICS INCORPORATED ("PRELUDE" OR THE "COMPANY") (NASDAQ: PRLD). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF PRELUDE THERAPEUTICS INCORPORATED - PRLD

LEAD CANDIDATE FROM MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PROGRAM ADVANCING WITH IND FILING EXPECTED IN THE FIRST QUARTER OF 2026

PRELUDE THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

PRELUDE TO PRIORITIZE DEVELOPMENT OF MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR AND KAT6A SELECTIVE DEGRADER PROGRAMS PAUSING FURTHER CLINICAL DEVELOPMENT OF SMARCA2 SELECTIVE DEGRADER PROGRAMS JAK2V617F OPTION AGREEMENT WITH INCYTE, AS PREVIOUSLY ANNOUNCED, INCLUDES UPFRONT PAYMENT OF $35 MILLION, A $25 MILLION EQUITY INVESTMENT AND $100 MILLION IF OPTION IS EXERCISED CUMULATIVE CAPITAL EXPECTED TO FUND PLANNED OPERATIONS INTO 2027 BASED ON THE COMPANY'S PRELIMINARY ESTIMATES, AND POTENTIALLY INTO THE THIRD QUARTER OF 2028 IF INCYTE EXERCISES OPTION ON JAK2 PROGRAM COMPANY TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS AND CONDUCT AN INVESTOR CONFERENCE CALL ON NOVEMBER 12, 2025 WILMINGTON, DEL., NOV. 04, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A PRECISION ONCOLOGY COMPANY, TODAY IS PROVIDING A NUMBER OF STRATEGIC UPDATES, INCLUDING ITS RECENTLY EXECUTED OPTION AGREEMENT WITH INCYTE CORPORATION CENTERED ON ITS PREVIOUSLY UNDISCLOSED JAK2V617F MUTANT SELECTIVE INHIBITOR PROGRAM, PRIORITIZING DEVELOPMENT OF ITS FIRST-IN-CLASS KAT6A SELECTIVE DEGRADER PROGRAM AND PAUSING OF ITS SMARCA2 PROGRAMS.

Prelude Therapeutics Incorporated

PRLD

Price

Financial Reports

No items found.

Press Releases

Prelude Therapeutics Incorporated

PRLD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PRLD